Related Experiment Video
Updated: Jul 30, 2025
09:29
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
13.8K
Developments in Checkpoint Inhibitor Therapy for the Management of Deficient Mismatch Repair (dMMR) Rectal Cancer.
Alan Su1, Rodrigo Pedraza2, Hagen Kennecke1,3
1Providence Cancer Institute Franz Clinic, Portland, OR 97232, USA.
Current Oncology (Toronto, Ont.)
|May 15, 2023
Summary
Immune checkpoint inhibition (ICI) shows promise for deficient mismatch repair (dMMR) rectal cancer, offering an alternative to chemotherapy. However, managing immune-related side effects and long-term outcomes requires further investigation.
Area of Science:
- Oncology
- Immunotherapy
- Gastroenterology
Background:
- Deficient mismatch repair (dMMR)/microsatellite instability-high (MSIH) colorectal cancer exhibits resistance to traditional chemotherapy.
- Immune checkpoint inhibition (ICI) presents a potential therapeutic strategy for these tumors.
Observation:
- This review focuses on the standard of care for locally advanced dMMR rectal cancer, emphasizing ICI.
- A case report illustrates the complexities and challenges associated with this novel treatment approach.
Findings:
- ICI can induce robust treatment responses in neoadjuvant settings for dMMR rectal cancer.
- Immune-related adverse events (irAEs) are a significant concern, potentially leading to treatment discontinuation.
Implications:
- ICI introduces new challenges in surveillance and surgical management for rectal cancer patients.
- Further research is needed to determine the long-term impact of neoadjuvant ICI on durable response and organ preservation.
Related Concept Videos
02:34Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K